Home › Intelligence › Flash

City Therapeutics Files S-1 Registration for NASDAQ IPO

Flash2026-10-16

City Therapeutics, Inc. filed its Form S-1 registration statement with the U.S. Securities and Exchange Commission on October 15, 2026, initiating its NASDAQ IPO process. The clinical-stage biotech focuses on novel antifibrotic therapies. The filing does not disclose expected offering size or ticker symbol, but marks the formal commencement of its U.S. listing journey.

51CFO view：S-1 filing demands immediate CFO readiness: GAAP-compliant financials (including ASC 718 equity accounting), SOX 404 internal controls documentation, and audit-ready systems traceable to at least 24 months pre-filing. CFO must lead cross-functional alignment with legal, audit, and underwriters from Day 1.

City Therapeutics, Inc. filed its Form S-1 registration statement with the U.S. Securities and Exchange Commission on October 15, 2026, initiating its NASDAQ IPO process. The clinical-stage biotech focuses on novel antifibrotic therapies. The filing does not disclose expected offering size or ticker symbol, but marks the formal commencement of its U.S. listing journey.

Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search

Where this touches your finance hire

Every listing event changes what you need from a CFO. Start from the step you are actually at.

What kind of CFO does a US IPO need? S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements. Read → Who owns SEC reporting and US GAAP? Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments. Read → Who runs finance through a SPAC merger? De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ. Read →
‹ Retension Pharmaceuticals Prices Upsized $45M IPO, Begins Nasdaq Trading
MED-X Files S-1/A Amendment Ahead of NASDAQ IPO ›